Central Nervous System Biomarkers Market

The global central nervous system biomarkers market size was valued at USD 4,652 million in 2020 and is expanding at considerable a CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the biomarkers for the central nervous system that have progressed in terms of technology.
 

Get Free Sample Report

A biomarker is a molecule that is used to assess the biological condition, the existence of illnesses, and the treatment effects. Over the last decade, advances in genomics and proteomics have increased understanding of genetic regulatory mechanisms associated with (central nervous system) CNS biomarkers. Through a comparison of normal and sick tissues, proteomics technologies have improved in numerous fields of drug discovery and development. The identification of useful protein biomarkers in both diagnostics and treatments for the central nervous system is a major goal of proteomics research. It is critical in the early diagnosis, prognosis, and monitoring of illness.

According to our database, global GDP fell by 4.5 per cent in May 2021, resulting in a loss of USD 3.94 trillion in economic activity. The consequences were also seen in the worldwide market for CNS biomarkers. In the early stages of the pandemic, the rate of patient screening and diagnosis was significantly hampered because governments throughout the world-imposed restrictions such as lockdowns to prevent the illness from spreading. According to a report released by the American Cancer Society in 2021, delays in cancer screening, diagnosis, and treatment would almost certainly result in a short-term decrease in cancer diagnoses, followed by an increase in late-stage diagnoses and unnecessary cancer deaths due to limited healthcare coverage.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing use of CNS biomarkers in neurodegenerative disease diagnosis is projected to spur market expansion in the coming years.
• Expensive biomarker testing and diagnostics for the central nervous system is estimated to hinder the market growth.
• Biomarkers of the central nervous system and their regulatory implications is expected to impede market growth.
• Growing number of diseases and improvement in the healthcare infrastructure is anticipated to create immense opportunities for the market players.

Scope of the Report

The report on the global central nervous system biomarkers market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Personalized medicine segment is projected to account for a key market share
In terms of applications, the central nervous system biomarkers market is segregated into drug discovery and development, personalized medicine, and other applications. The personalized medicine segment is expected to account for a key share of the market during the forecast period owing to the growing frequency of the brain and other nervous system tumors. It is finding increasing use as a diagnostic tool, assisting in the identification of precise biological markers. A growing number of firms are focusing their efforts on creating breakthrough solutions for the treatment of neurological disorders.

Biomarker research in neurodegenerative illness is a field of personalized medicine that is fast progressing. These indicators can be used for more than just diagnosis; they can also be used to predict prognosis or aid in the development of novel treatments. As a result, a significant number of compounds have been studied and linked to various neurodegenerative diseases. The two most prevalent neurodegenerative illnesses are Alzheimer's disease and Parkinson's disease.
 

Get Free Sample Report

North America is expected to dominate the market

On the basis of regions, the central nervous system biomarkers market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to the rising burden of chronic illnesses, advances in proteomics, genomics, and imaging technologies.

According to GLOBOCAN projections, in 2020, there will be 2,281,658 new cancer cases diagnosed and 612,390 cancer-related deaths in the United States. The National Institute of Neurological Disorders and Stroke is largely focused on methods that might speed up the development and validation of reliable biomarkers, particularly for improved diagnosis and treatment of specific diseases.
 

Get Free Sample Report

Segments

Segments Covered in the Report
The global central nervous system biomarkers market has been segmented on the basis of

Applications

• Drug Discovery and Development
• Personalized Medicine
• Other Applications

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Thermo fisher scientific
• Enzo biochem inc
• Abiant Inc
• EKF diagnostics holdings Inc
• Abastar MDX Inc
• Acumen Pharmaceuticals Inc
• Adlyfe Inc
• Apitope international
• Alseres pharmaceuticals Inc
• Aposense
• Banyan biomarkers
• Avid radiopharmaceuticals Inc
• Diagenic ASA
• Avacta Group plc
• Applied neurosolutions Inc
• Merc & co. Inc
• Exonhit therapeutics

Competitive Landscape

Key players competing in the central nervous system biomarkers market include Thermo fisher scientific, Enzo biochem inc, Abiant Inc, EKF diagnostics holdings Inc, Abastar MDX Inc, Acumen pharmaceuticals Inc, Adlyfe Inc, Apitope international, Alseres pharmaceuticals Inc, Aposense, Banyan biomarkers, Avid radiopharmaceuticals Inc, Diagenic ASA, Avacta Group plc, Applied neurosolutions Inc, Merc & co. Inc, and Exonhit therapeutics.